Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE

More documents

Recommendations

Info

4 ICER Thresholds KCE Reports 100 potentielle) Efficiency (efficiëntie/doelmatigheid; efficience) In economic theory defined as the condition in which no productive resources are wasted in the manufacture of a certain product; i.e. where output is produced at minimum cost or the level of output is maximised at a given cost (i.e. cannot be increased). In health care, efficiency implies that choices should be made so as to derive the maximum total health benefit from the available resources. ‘Allocative efficiency’ occurs when the outcomes achieved with the available resources match the priorities of society. Health-related quality of life A multidimensional construct measuring the physical, social and emotional aspects that are relevant and important to a patient’s well-being. Health maximisation Maximisation of relevant health outcomes. In health economics often maximisation of the number of LYG or the number of QALYs gained. Health outcome Result of health intervention for the health of a patient or a population. ICER threshold value Benchmark for ICERs (incremental cost-effectiveness ratios) to assess an intervention’s cost-effectiveness. Interventions with an ICER below the ICER threshold value are considered costeffective, interventions with an ICER above the ICER threshold value are not cost-effective. Incremental analysis Analysis of additional costs and additional health outcomes Incremental cost-effectiveness ratio (ICER) associated with different treatments. Ratio of additional costs and additional health outcomes associated with different treatments: (C 2 – C 1)/(E 2 – E 1), where C 2 and C 1 represent the costs of intervention 2 and 1 respectively and E 2 and E 1 represent the health outcomes (effects) of intervention 2 and 1 respectively. League table Table ranking health interventions according to their incremental cost-effectiveness ratio with the purpose to guide resourceallocation decisions. Opportunity costs The costs of resources consumed expressed as the value of the next best alternative for using these resources. Private insurance based health System where health care is funded from premiums paid to care system private insurance companies. Quality-adjusted life year Measure for health outcomes that includes both quality and quantity of life a patient is expected to have. Quality-adjusted life years are calculated by estimating the total life years gained from a treatment and weighting each time period within these life years gained with a quality-of-life score between 0 (dead) to 1 (perfect health) that reflects the health-related quality of life in that period. Sensitivity analysis Technique used in economic evaluation to allow for uncertainty by testing whether plausible changes in the values of the main variables affect the results of the analysis. Societal Willingness to Pay (WTP) Societal willingness to pay refers to the maximum amount society is willing to pay for a unit of health gain (e.g. QALY or life-year gained). It reflects what society is willing to sacrifice in terms of other goods or services for a unit of health gain. Uncertainty A state in which the true value of a parameter or the structure of a process is unknown. Utility A measure of the preference for, or desirability of, a specific level of health status or specific health outcomes.
KCE reports 100 ICER Thresholds 5 ABBREVIATIONS CADTH Canadian Agency for Drugs and Technologies in Health CBA Cost-Benefit Analysis CEA Cost-Effectiveness Analysis CEDAC Canadian Expert Drug Advisory Committee CTG/CRM Drug Reimbursement Committee (Commissie Tegemoetkoming Geneesmiddelen/Commission de Remboursement des Médicaments) (=DRC) (Belgium) CUA Cost-Utility Analysis CVZ Dutch Health care Insurance Board (College voor zorgverzekeringen) DACEHTA Danish Centre for Health Technology Assessment DRC Drug Reimbursement Committee (=CTG/CRM) (Belgium) FOD/SPF Federal Public Service (Federale Overheidsdienst / Service Public Fédéral) (=FPS) (Belgium) FPS Federal Public Service (=FOD/SPF) (Belgium) GDP Gross Domestic Product HPV Human Papillomavirus HRQoL Health-Related Quality of Life ICER Incremental Cost-Effectiveness Ratio KCE Belgian Health Care Knowledge Centre (Federaal Kenniscentrum voor de Gezondheidszorg / Centre fédéral d’expertise des soins de santé (Belgium) MCDA Multi-Criteria Decision Analysis MRI Magnetic Resonance Imaging NHS National Health Service NICE National Institute for Health and Clinical Excellence (UK) NIHDI National Institute for Health and Disability Insurance (=RIZIV/INAMI) (Belgium) PBAC Pharmaceutical Benefits Advisory Committee (Australia) PET Positron Emission Tomography PHARMAC Pharmaceutical Management Agency (New Zealand) QALY Quality-Adjusted Life Year RIZIV/INAMI National Institute for Health and Disability Insurance (Rijksinstituut voor Ziekte- en Invaliditeitsverzekering/National d’Assurance Maladie- Invalidité) (=NIHDI) (Belgium) TCI Technical Council for Implants (=TRI/CTI) (Belgium) TRI/CTI Technical Council for Implants (Technische Raad voor Implantaten/Conseil Technique des Implants) (=TCI) (Belgium) WTP Willingness-To-Pay
Page 1 and 2: Valeurs seuils pour le rapport coû
Page 3 and 4: Valeurs seuils pour le rapport coû
Page 5 and 6: KCE Reports 100B Utilisations des v
Page 13 and 14: KCE reports 100 ICER Thresholds 1 S
Page 15: KCE reports 100 ICER Thresholds 3 G
Page 19 and 20: KCE reports 100 ICER Thresholds 7 1
Page 21 and 22: KCE reports 100 ICER Thresholds 9 2
Page 23 and 24: KCE reports 100 ICER Thresholds 11
Page 67 and 68:
KCE reports 100 ICER Thresholds 55
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81:
Page 84 and 85:
Dépôt légal : D/2009/10.273/95
Page 86 and 87:
35. Etude relative aux coûts poten
show all

Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE

Create successful ePaper yourself

Delete template?

Save as template?